Baseline characteristics of cGVHD at onset before institution of therapy
| . | n (%) . |
|---|---|
| Mode of presentation of cGVHD | |
| Progressive | 53/151* (35.1) |
| Quiescent | 67/151 (44.4) |
| De novo | 31/151 (20.5) |
| Histology of cGVHD | |
| Lichenoid | 121/149 (81.2) |
| Sclerodermatous +/− lichenoid features | 28/149 (18.8) |
| Biopsy sites for the diagnosis of cGVHD | |
| Skin | 117/149 (78.5) |
| Lip, buccal mucosa, or salivary gland | 65/149 (43.6) |
| Liver | 18/149 (12.1) |
| Gut | 2/149 (1.3) |
| Weight loss (%) | |
| None | 41/150 (27.3) |
| < 10% from baseline (BMT) | 50/150 (33.3) |
| ≥ 10% from baseline (BMT) | 59/150 (39.4) |
| Thrombocytopenia (< 100 000/mm3) | 71/151 (47.0) |
| Eosinophilia (> 4%) | 50/149 (33.6) |
| Hyperbilirubinemia (> 1.2 mg/dL) | 68/151 (45.0) |
| Elevated alkaline phosphatase (> 200 U/L) | 64/151 (42.4) |
| Decreased serum IgG (< 500 mg/dL) | 66/147 (44.9) |
| Skin extent | |
| Code 1 | 32 (21.2) |
| Code 2 | 52 (34.4) |
| Code 3 | 67 (44.4) |
| Initial immunosuppressive therapy† | |
| Local ± single systemic ± PUVA | 34/149 (22.8) |
| Double systemic ± PUVA | 66/149 (44.3) |
| Triple systemic ± PUVA | 49/149 (32.9) |
| . | n (%) . |
|---|---|
| Mode of presentation of cGVHD | |
| Progressive | 53/151* (35.1) |
| Quiescent | 67/151 (44.4) |
| De novo | 31/151 (20.5) |
| Histology of cGVHD | |
| Lichenoid | 121/149 (81.2) |
| Sclerodermatous +/− lichenoid features | 28/149 (18.8) |
| Biopsy sites for the diagnosis of cGVHD | |
| Skin | 117/149 (78.5) |
| Lip, buccal mucosa, or salivary gland | 65/149 (43.6) |
| Liver | 18/149 (12.1) |
| Gut | 2/149 (1.3) |
| Weight loss (%) | |
| None | 41/150 (27.3) |
| < 10% from baseline (BMT) | 50/150 (33.3) |
| ≥ 10% from baseline (BMT) | 59/150 (39.4) |
| Thrombocytopenia (< 100 000/mm3) | 71/151 (47.0) |
| Eosinophilia (> 4%) | 50/149 (33.6) |
| Hyperbilirubinemia (> 1.2 mg/dL) | 68/151 (45.0) |
| Elevated alkaline phosphatase (> 200 U/L) | 64/151 (42.4) |
| Decreased serum IgG (< 500 mg/dL) | 66/147 (44.9) |
| Skin extent | |
| Code 1 | 32 (21.2) |
| Code 2 | 52 (34.4) |
| Code 3 | 67 (44.4) |
| Initial immunosuppressive therapy† | |
| Local ± single systemic ± PUVA | 34/149 (22.8) |
| Double systemic ± PUVA | 66/149 (44.3) |
| Triple systemic ± PUVA | 49/149 (32.9) |